← Eichor
Study identifier: NCT06313749 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

Condition: Primary Open Angle Glaucoma · Open Angle Glaucoma  ·  Sponsor: Sanoculis Ltd

PhaseNA
Planned participants129
Who can joinAll sexes, 40 Years to 85 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to show non-inferiority of the MIMS® device/procedure with Mitomycin-C, in terms of its surgical success rate, compared to trabeculectomy with Mitomycin-C in subjects diagnosed with primary open angle glaucoma, whose intraocular pressure is not controlled despite polypharmacy. Eligible screened participants will undergo the MIMS® procedure and will be followed for a period of 12 months in this single-arm study. Investigators will compare the results of this study to the surgical success rate of traditional trabeculectomy with Mitomycin-C.

This description comes directly from the study's public registry record.

Talk to the study team

Khan Lau, OD  ·  8082862666  ·  khan@sanoculis.com

Always discuss trial participation with your own doctor first.

Locations (1)

Glaucoma Associates of TexasDallas, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06313749